Low molecular weight heparins in the prevention of deep-vein thrombosis in general surgery.
Unfractionated heparin (UFH) was the established treatment in the early 1980s for the prophylaxis of venous thromboembolic disease (VTED) in patients undergoing general surgery. This was one of the earliest indications in which low molecular weight heparins (LMWHs) were tested, and about 40 trials have revealed that these agents are at least as effective and safe as UFH with a tendency of superiority when higher dosages are used. In most trials, the fibrinogen uptake test has been used to assess the frequency of deep vein thrombosis. LMWHs exhibit a number of improved features over UFH, including ease of administration and convenient once daily dosing, facilitating outpatient management. A still open question is the ideal time and dose of the first one or two injections of a LMWH. To determine the clinical relevance of product differentiation further, clinical trials, directly comparing different LMWHs, are required.
Breddin
H K
HK
International Institute of Thrombosis and Vascular Diseases, Frankfurt/Main, Germany.
D017985:Dalteparin / Q000627:therapeutic use; D006470:Hemorrhage / Q000209:etiology; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D017762:Nadroparin / Q000627:therapeutic use; D013514:Surgical Procedures, Operative; D020246:Venous Thrombosis / Q000209:etiology / Q000517:prevention & control*
D006495:Heparin, Low-Molecular-Weight; D017762:Nadroparin; D017985:Dalteparin